West Pharma (WST) Tops Q1 EPS by 26c, provides guidance

West Pharma (NYSE: WST) reported Q1 EPS of $1.56, $0.26 better than the analyst estimate of $1.30. Revenue for the quarter came in at $695.4 million versus the consensus estimate of $670.31 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $7.63-$7.88, versus the consensus of $7.63. West Pharma sees FY2024 revenue of $3-3.025 billion, versus the consensus of $3.011 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance